Emletra Tablet Substitute

Substitutes of Emletra Tablet meet the same safety and efficacy standards as Emletra Tablet, but small differences in absorption or formulation can exist. A doctor can help you choose the right one for your needs.

Yes. Substitutes of Emletra Tablet may vary in color, size, or shape due to differences in manufacturing and branding, but this does not affect how they work.

Yes, it’s generally safe to switch between multiple substitutes of Emletra Tablet if they have the same salt and strength. However, always inform your doctor so they can monitor how your body responds.

Yes, many people safely use substitutes of Emletra Tablet for long-term treatment. Just ensure it’s done under medical supervision.

If your symptoms stay under control or lab results remain stable, the substitute for Emletra Tablet is likely working well. Regular follow-ups with your doctor are important.

Absolutely. Even with the same salt, small differences can affect how your body responds when switching from Emletra Tablet to its substitute. Always consult your doctor before switching.

Emletra Tablet contains Lopinavir and Ritonavir. Lopinavir works by inhibiting the working of a protease enzyme that is essential for the reproduction of the HIV virus. Thereby, it prevents the production of the new virus. Ritonavir slows the breakdown of Lopinavir by the liver and increases the levels of Lopinavir in blood and makes it effective against the virus. Together, they help to control HIV infection.

Emletra Tablet should be used with caution in diabetic patients as it may increase blood sugar levels. However, if you experience increased thirst or urination, weight loss or fruity breath smell while taking Emletra Tablet, please consult a doctor immediately as these might be signs of high blood sugar levels.

Emletra Tablet may cause bone problems such as osteonecrosis (death of bone tissue due to loss of blood supply to the bone) especially in HIV patients taking combination antiretroviral therapy. However, if you experience joint pains, stiffness (especially of shoulder, knee or hip) or difficulty in movement, please consult a doctor immediately.

HIV infection may still be transmitted to other persons while using Emletra Tablet. Emletra Tablet reduces the risk of transmission but still, HIV infection is contagious. Therefore, discuss with a doctor regarding precautions to be taken to avoid transmission of HIV while taking Emletra Tablet.

Emletra Tablet is not recommended for patients with severe liver problems including chronic hepatitis B or C infection as it may increase the risk of severe liver side effects. Therefore, inform your doctor if you have a history of any liver problems before taking Emletra Tablet.

Emletra Tablet does not cure HIV infection. Emletra Tablet reduces the amount of HIV virus in the body and improves the functioning of the immune system.